Highlights Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Market Closed - Australian S.E. Other stock markets 07:10:13 28/06/2024 BST			5-day change	1st Jan Change
0.062 ^AUD	+34.78%		+93.75%	+181.82%

06-26	Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	CI
06-26	Actinogen Medical's Xanamem Drug 'Potentially Slows' Progression of Alzheimer's Disease	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	06-26	CI
Actinogen Medical's Xanamem Drug 'Potentially Slows' Progression of Alzheimer's Disease	06-26	MT
Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer	05-30	MT
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	05-15	MT
Rights Issue: 1 new share @ 0.025 AUD for 15 existing shares	05-08	FA
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	05-03	MT
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	04-22	CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	04-22	MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	04-15	CI
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	03-25	MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-25	CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	02-15	MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	11-28	CI
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	11-28	MT
Actinogen Medical Limited Announces CFO Changes	11-07	CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	13/10/23	CI
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	26/09/23	CI
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30/08/23	CI
Rights Issue: 100 new shares @ 0.025 AUD for 454 existing shares	10/08/23	FA
Companies in Alzheimer's race after US nod for Eisai/Biogen drug	07/07/23	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Highlights

Filters